NCT07355205
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07355205
Title First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)
Acronym FLINN
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Washington University School of Medicine
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA